Q1 2025 Management View CEO Sam Raha opened the call by highlighting a challenging Q1 2025, with revenue of $196 million, ...

Genetic testing company Myriad Genetics (NASDAQ:MYGN) in Q1 CY2025, with sales falling 3.1% year on year to $195.9 million.

First quarter 2025 Prenatal revenue grew 11% year-over-year, while Pharmacogenomics revenue declined by 20% year-over-year ...

While the top- and bottom-line numbers for Myriad (MYGN) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to ...

Myriad Genetics' growth potential lies in its innovative products, strong financials, and expanding market opportunities.

Myriad Genetics. “Expanding access through CancerCARE’s network will give more patients the opportunity to take the MyRisk with RiskScore Hereditary Cancer Test.” MyRisk with RiskScore is ...

In the latest quarter, 10 analysts provided ratings for Myriad Genetics MYGN, showcasing a mix of bullish and bearish perspectives. The table below provides a concise overview of recent ratings by ...

Myriad Genetics, Inc. SALT LAKE CITY, April 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today ...

Myriad Genetics has a 1 year low of $7.16 and a ... It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline ...

Myriad Genetics (NASDAQ:MYGN – Free Report ... It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline ...